Table 2.

Therapeutic antibodies that are being evaluated in the clinical trials.

Source	Target	Name	Clinical trial	References
Viral	Env CD4 binding site	3BNC117	Phase 2a	[43]
	Env V3 glycan site	10-1074	Phase I	[44]
	Env CD4 binding site	VRC01	Phase I	[45]
	V1V2	PGDM1400	Phase I	[42]
	Env V3 glycan site	PGT121	Phase I	[46]
	Env MPER	10E8v4	Phase I	[47]
	Env CD4 binding site	N6	Phase II	[42]
Cellular	CCR5	HGS004	Phase I	[48]
	CCR5	PRO140	Phase III	[49]
	CCR5/CCR2	Cenicriviroc	Phase III	[50]
	CD4	TMB-355	Phase III	[51]
	PDL1	BMS-936559	Phase I	[52]